Telix Pharmaceuticals (TLPPF) Intangibles (2023 - 2024)
Telix Pharmaceuticals' (TLPPF) quarterly Intangibles came in at $272.1 million in Q4 2024, up 281.2% year-over-year from $71.4 million in Q1 2024, and up 281.2% quarter-over-quarter from $71.4 million in Q4 2023.
Powered by 
Analysis
Telix Pharmaceuticals (TLPPF) Intangibles (2023 - 2024) Analysis & Trends
Telix Pharmaceuticals (TLPPF) has reported Intangibles for 2 consecutive years, with $272.1 million the latest figure, recorded in Q4 2024.
- On a quarterly basis, Intangibles rose 281.2% year-over-year to $272.1 million in Q4 2024; TTM through Dec 2024 was $272.1 million, a 281.2% increase from a year earlier, with the FY2024 full-year figure at $272.1 million, up 281.2% from the prior year.
- Intangibles was $272.1 million for Q4 2024 at Telix Pharmaceuticals, up from $71.4 million in the prior quarter.
- Over five years, Intangibles peaked at $272.1 million in Q4 2024 and troughed at $71.4 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.49 Bn | 198.50 Bn | 7.24 Bn | 20.49 Bn |
| 2 | Gilead Sciences | 180.93 Bn | 177.75 Bn | 6.22 Bn | 14.03 Bn |
| 3 | Vertex Pharmaceuticals | 132.39 Bn | 124.53 Bn | 2.84 Bn | 412.80 Mn |
| 4 | Regeneron Pharmaceuticals | 82.17 Bn | 74.18 Bn | 3.93 Bn | 1.31 Bn |
| 5 | Argenx Se | 61.05 Bn | 55.87 Bn | 1.37 Bn | 266.00 Mn |
| 6 | Moderna | 55.19 Bn | 50.05 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.99 Bn | 30.68 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.30 Bn | 30.01 Bn | 1.96 Bn | 13.52 Bn |
| 9 | Roivant Sciences | 29.91 Bn | 29.91 Bn | 1.16 Mn | - |
| 10 | Telix Pharmaceuticals | 3.72 Bn | 3.43 Bn | - | - |